Description:
<jats:p>Modeling can play a vital role in predicting, optimizing and analyzing the results of therapeutic ultrasound treatments. Simulating the propagating acoustic beam in various targeted regions of the body allows for the prediction of the resulting power deposition and temperature profiles. In this session we will apply various modeling approaches to breast, abdominal organ and brain treatments. Of particular interest is the effectiveness of procedures for correcting for phase aberrations caused by intervening irregular tissues, such as the skull in transcranial applications or inhomogeneous breast tissues. Also described are methods to compensate for motion in targeted abdominal organs such as the liver or kidney.</jats:p><jats:p>Douglas Christensen – Modeling for Breast and Brain HIFU Treatment Planning</jats:p><jats:p>Tobias Preusser – TRANS‐FUSIMO – An Integrative Approach to Model‐Based Treatment Planning of Liver FUS</jats:p><jats:p>Tobias Preusser – TRANS‐FUSIMO – An Integrative Approach to Model‐Based Treatment Planning of Liver FUS</jats:p><jats:p><jats:bold>Learning Objectives:</jats:bold>
<jats:list list-type="explicit-label">
<jats:list-item><jats:p>Understand the role of acoustic beam modeling for predicting the effectiveness of therapeutic ultrasound treatments.</jats:p></jats:list-item>
<jats:list-item><jats:p>Apply acoustic modeling to specific breast, liver, kidney and transcranial anatomies.</jats:p></jats:list-item>
<jats:list-item><jats:p>Determine how to obtain appropriate acoustic modeling parameters from clinical images.</jats:p></jats:list-item>
<jats:list-item><jats:p>Understand the separate role of absorption and scattering in energy delivery to tissues.</jats:p></jats:list-item>
<jats:list-item><jats:p>See how organ motion can be compensated for in ultrasound therapies.</jats:p></jats:list-item>
<jats:list-item><jats:p>Compare simulated data with clinical temperature measurements in transcranial applications.</jats:p></jats:list-item>
</jats:list></jats:p><jats:p>Supported by NIH R01 HL172787 and R01 EB013433 (DC); EU Seventh Framework Programme (FP7/2007‐2013) under 270186 (FUSIMO) and 611889 (TRANS‐FUSIMO)(TP); and P01 CA159992, GE, FUSF and InSightec (UV).</jats:p>